Top Markets
#1 NKN NKN +148.63%
#2 Black Phoenix Black Phoenix +99.30%
#3 Codatta Codatta +29.58%
#4 SAFEcoin SAFEcoin +28.41%
#5 Bluwhale Bluwhale +27.83%
#6 Saakuru Saakuru +24.27%
#7 StakeStone StakeStone +22.52%
#8 Particle Network Particle Network +17.58%
#9 Yooldo Games Yooldo Games +16.68%
#10 Arcblock Arcblock +16.01%
Coin of the day
NKN NKN
Settings
Language
ENGLISH
Currency
USD
Theme
Intellipharmaceutics International Inc. Intellipharmaceutics International Inc.

Intellipharmaceutics International Inc.

IPCIF
Rank in Stocks #99999
Intellipharmaceutics International Inc., a pharmaceutical company, researches,... Intellipharmaceutics International Inc., a pharmaceutical company, researches, develops, and manufactures novel and generic controlled-release and targeted-release oral solid dosage drugs in the United States. It develops various drug delivery systems, product candidates, and a pipeline of products based on its patented Hypermatrix technology in various therapeutic areas, including neurology, cardiovascular, gastrointestinal tract, diabetes, and pain. The company offers Focalin XR, a dexmethylphenidate hydrochloride extended-release capsule for hyperactivity disorder; Keppra XR, a levetiracetam extended-release tablet for the treatment of partial onset seizures in patients with epilepsy; Effexor XR, a venlafaxine hydrochloride extended-release capsule to treat depression; and Protonix, a pantoprazole sodium delayed-release tablet to treat gastroesophageal reflux disease. It also provides Glucophage XR, a metformin hydrochloride extended-release tablet that treats type 2 diabetes; Seroquel XR, a quetiapine fumarate extended-release tablet for the treatment of schizophrenia, bipolar disorder, and major depressive disorders; Lamictal XR, a lamotrigine extended release tablet to treat epilepsy; Pristiq, a desvenlafaxine extended-release tablet to treat depression; Coreg CR, a carvedilol phosphate extended-release capsule for heart failure and hypertension; and Ranexa, a ranolazine extended release tablet for chronic angina. In addition, the company is developing OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; OxyContin, an oxycodone hydrochloride controlled-release capsule for pain; and Regabatin XR, a pregabalin extended-release capsule for the management of neuropathic pain. It has a license and commercialization agreement with Par Pharmaceutical Inc. The company was founded in 1998 and is based in Toronto, Canada.
Share Price
$0.15
Market Cap
$4.96M
Change (1 day)
0.00%
Change (1 year)
0.00%
Country
CA
Trade Intellipharmaceutics International Inc. (IPCIF)

Category

Healthcare
Revenue for Intellipharmaceutics International Inc. (IPCIF)
Revenue in Aug 2023 TTM: $904.95K
According to Intellipharmaceutics International Inc. latest financial reports the company's current revenue (TTM) is $904.95K. In 2021 the company made a revenue of $65.73K a decrease compared to the revenue in the year 2020 that was $1.40M. The revenue is the total amount of income that a company generates by the sale of goods or services. Unlike with the earnings no expenses are subtracted.
Revenue history for Intellipharmaceutics International Inc. from 1999 to 2026
Revenue at the end of each year
Year Revenue Change
2026 (TTM) $904.95K 1,276.80%
2022 $65.73K 0.00%
2021 $65.73K -95.31%
2020 $1.40M 0.00%
2019 $1.40M -18.17%
2018 $1.71M -68.88%
2017 $5.50M 144.97%
2016 $2.25M -45.11%
2015 $4.09M -53.32%
2014 $8.77M 474.13%
2013 $1.53M 1,326.33%
2012 $107.09K -78.66%
2011 $501.81K -65.61%
2010 $1.46M 0.00%
2008 0.00 0.00%
2007 0.00 0.00%
2006 0.00 0.00%
2005 0.00 0.00%
2004 0.00 0.00%
2003 0.00 0.00%
2002 0.00 -100.00%
2001 $1.00K 0.02%
2000 $999.82 -99.00%
1999 $100.06K 0.00%
Revenue for similar companies or competitors
Company Revenue Revenue Difference Country
Novo Nordisk A/S Novo Nordisk A/S
Novo Nordisk A/S
NVO.US
 $48.44B 5,352,315.73%
DK
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 $12.04B 1,330,189.32%
US
Regeneron Pharmaceuticals, Inc. Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
REGN.US
 $14.34B 1,584,845.40%
US
UCB SA UCB SA
UCB SA
UCB.BR
 $9.08B 1,003,525.57%
BE
Argenx SE Argenx SE
Argenx SE
ARGX.US
 $5.49B 606,708.00%
NL